Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
An RX mirror and its underlying label are not independent clinical confirmations.
Check source scope before reading a dose
WAINUA: recovered RX renal use section
Product / population
Adult WAINUA subcutaneous eplontersen for labeled hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Renal method
eGFR >=30 to <90 mL/min/1.73 m2 in section 8.6
Source revision
Not established in reviewed passage
Retrieved
2026-11-07
Local review status
Selected named sections summarized; not a complete monograph or independent clinician approval.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
A bounded no-adjustment statement
The no-adjustment statement applies to the renal range studied, not to severe impairment or end-stage disease.
What to reconcile: Keep indexed eGFR units and the unstudied population warning attached to the answer.
Recovered mirror does not resolve severe impairment or ESRD
The previously unavailable RX renal passage is now retained. Its eGFR range and severe/ESRD gap agree with the selected official passage, but share a label lineage.
What to reconcile: Use indexed eGFR as printed and keep severe impairment and dialysis as open evidence limits.
GlobalRPh RX List / label mirror · Adult WAINUA subcutaneous eplontersen for labeled hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Renal method: eGFR >=30 to <90 mL/min/1.73 m2 in section 8.6 Source date: Not established in reviewed passage Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding
Confirm product, indication, renal measure and dialysis modality before applying.
Dialysis evidence: No dialysis regimen established in selected content
Selected named sections summarized; not a complete monograph or independent clinician approval.
Selected renal sections
No adjustment is described for eGFR at least 30 but below 90 mL/min/1.73 m2. Severe impairment and ESRD were not studied. Preserve the indexed units from section 8.6; do not infer a dialysis regimen. This recovered mirror is not independent confirmation of the label.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
